Skip to content

Analysis of therapeutic effect of ultrasound-guided thermal ablation on T1-2N0M0 papillary thyroid carcinoma

Analysis of therapeutic effect of ultrasound-guided thermal ablation on T1-2N0M0 papillary thyroid carcinoma

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082740
Enrollment
Unknown
Registered
2024-04-07
Start date
2022-10-10
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Papillary carcinoma of thyroid

Interventions

Thermal ablation Group (Retrospective study):NA
Thermal ablation Group (Prospective study):ultrasound-guided thermal ablation on T1-2N0M0 papillary thyroid carcinoma

Sponsors

First Affiliated Hospital of Dalian Medical University, Dalian, China
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) the cytological examination of fine needle aspiration biopsy or the pathological examination of thick needle aspiration biopsy before operation suggested that the primary papillary thyroid carcinoma (2) the tumor was confined to the thyroid gland, thyroid papillary carcinoma (T1-2N0M0) without invasion of thyroid capsule and surrounding tissues (3) patients without suspected metastatic lymph nodes or distant metastasis on imaging; (4) patients who could not tolerate or were unwilling to undergo surgery and who refused the clinical observer (patient requested minimally invasive intervention) and who agreed to participate in this clinical trial and voluntarily signed an informed consent form

Exclusion criteria

Exclusion criteria: 1. Invasion of the thyroid capsule and surrounding tissue, ultrasonography and CT scan showed the presence of regional lymph node or distant metastasis, which was confirmed by biopsy. 2. Non-papillary carcinoma was confirmed by biopsy. 3. Severe coagulation dysfunction or severe cardiopulmonary insufficiency.

Design outcomes

Primary

MeasureTime frame
The total absorption rate of the ablation at 12 months after surgery;

Secondary

MeasureTime frame
Target lesion volume reduction rate 3 months after surgery;Target lesion volume reduction rate 6 months after surgery;Target lesion volume reduction rate 12 months after surgery;Rate of complete disappearance of target lesion after operation;Postoperative lymph node metastasis;Whether distant metastasis occurred after surgery;

Countries

China

Contacts

Public ContactYing Che

The First Affiliated Hospital of Dalian Medical University

yche1964@163.com+86 180 9887 7117

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026